144 related articles for article (PubMed ID: 38669256)
1. The KRAS, ATR and CHEK1 expression levels in endometrial cancer are the risk factors predicting recurrence.
Buchynska L; Gordiienko I; Glushchenko N; Iurchenko N
PLoS One; 2024; 19(4):e0302075. PubMed ID: 38669256
[TBL] [Abstract][Full Text] [Related]
2. KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.
Birkeland E; Wik E; Mjøs S; Hoivik EA; Trovik J; Werner HM; Kusonmano K; Petersen K; Raeder MB; Holst F; Øyan AM; Kalland KH; Akslen LA; Simon R; Krakstad C; Salvesen HB
Br J Cancer; 2012 Dec; 107(12):1997-2004. PubMed ID: 23099803
[TBL] [Abstract][Full Text] [Related]
3. Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer.
Abdel-Fatah TM; Middleton FK; Arora A; Agarwal D; Chen T; Moseley PM; Perry C; Doherty R; Chan S; Green AR; Rakha E; Ball G; Ellis IO; Curtin NJ; Madhusudan S
Mol Oncol; 2015 Mar; 9(3):569-85. PubMed ID: 25468710
[TBL] [Abstract][Full Text] [Related]
4. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
[TBL] [Abstract][Full Text] [Related]
5. Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Eskander RN; Ali S; Dellinger T; Lankes HA; Randall LM; Ramirez NC; Monk BJ; Walker JL; Eisenhauer E; Hoang BH
Int J Gynecol Cancer; 2016 Jan; 26(1):125-32. PubMed ID: 26397159
[TBL] [Abstract][Full Text] [Related]
6. The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905.
Lee LJ; Ratner E; Uduman M; Winter K; Boeke M; Greven KM; King S; Burke TW; Underhill K; Kim H; Boulware RJ; Yu H; Parkash V; Lu L; Gaffney D; Dicker AP; Weidhaas J
PLoS One; 2014; 9(4):e94167. PubMed ID: 24732316
[TBL] [Abstract][Full Text] [Related]
7. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.
Berg A; Hoivik EA; Mjøs S; Holst F; Werner HM; Tangen IL; Taylor-Weiner A; Gibson WJ; Kusonmano K; Wik E; Trovik J; Halle MK; Øyan AM; Kalland KH; Cherniack AD; Beroukhim R; Stefansson I; Mills GB; Krakstad C; Salvesen HB
Oncotarget; 2015 Jan; 6(2):1327-39. PubMed ID: 25415225
[TBL] [Abstract][Full Text] [Related]
8. KRAS mutation and microsatellite instability in endometrial adenocarcinomas showing MELF-type myometrial invasion.
Stewart CJ; Amanuel B; Grieu F; Carrello A; Iacopetta B
J Clin Pathol; 2010 Jul; 63(7):604-8. PubMed ID: 20591910
[TBL] [Abstract][Full Text] [Related]
9. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer.
Meyer LA; Slomovitz BM; Djordjevic B; Westin SN; Iglesias DA; Munsell MF; Jiang Y; Schmandt R; Broaddus RR; Coleman RL; Galbincea JM; Lu KH
Int J Gynecol Cancer; 2014 May; 24(4):713-7. PubMed ID: 24651628
[TBL] [Abstract][Full Text] [Related]
10. Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma.
Dobrzycka B; Terlikowski SJ; Mazurek A; Kowalczuk O; Niklińska W; Chyczewski L; Kulikowski M
Folia Histochem Cytobiol; 2009; 47(1):65-8. PubMed ID: 19419940
[TBL] [Abstract][Full Text] [Related]
11. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Sinicrope FA; Shi Q; Allegra CJ; Smyrk TC; Thibodeau SN; Goldberg RM; Meyers JP; Pogue-Geile KL; Yothers G; Sargent DJ; Alberts SR
JAMA Oncol; 2017 Apr; 3(4):472-480. PubMed ID: 28006055
[TBL] [Abstract][Full Text] [Related]
12. Modelling genetic and clinical heterogeneity in epithelial ovarian cancers.
Lawrenson K; Sproul D; Grun B; Notaridou M; Benjamin E; Jacobs IJ; Dafou D; Sims AH; Gayther SA
Carcinogenesis; 2011 Oct; 32(10):1540-9. PubMed ID: 21859834
[TBL] [Abstract][Full Text] [Related]
13. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
Tsang YT; Deavers MT; Sun CC; Kwan SY; Kuo E; Malpica A; Mok SC; Gershenson DM; Wong KK
J Pathol; 2013 Dec; 231(4):449-56. PubMed ID: 24549645
[TBL] [Abstract][Full Text] [Related]
14. Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma.
Kang S; Seo SS; Chang HJ; Yoo CW; Park SY; Dong SM
Int J Gynecol Cancer; 2008; 18(6):1339-43. PubMed ID: 18221484
[TBL] [Abstract][Full Text] [Related]
15. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
[TBL] [Abstract][Full Text] [Related]
16. Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis.
Mizumoto Y; Kyo S; Mori N; Sakaguchi J; Ohno S; Maida Y; Hashimoto M; Takakura M; Inoue M
Cancer Sci; 2007 May; 98(5):652-8. PubMed ID: 17388789
[TBL] [Abstract][Full Text] [Related]
17. The Role of KRAS in Endometrial Cancer: A Mini-Review.
Sideris M; Emin EI; Abdullah Z; Hanrahan J; Stefatou KM; Sevas V; Emin E; Hollingworth T; Odejinmi F; Papagrigoriadis S; Vimplis S; Willmott F
Anticancer Res; 2019 Feb; 39(2):533-539. PubMed ID: 30711927
[TBL] [Abstract][Full Text] [Related]
18. RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer.
Pijnenborg JM; Dam-de Veen GC; Kisters N; Delvoux B; van Engeland M; Herman JG; Groothuis PG
Ann Oncol; 2007 Mar; 18(3):491-7. PubMed ID: 17170014
[TBL] [Abstract][Full Text] [Related]
19. Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer.
van Weelden WJ; Lalisang RI; Bulten J; Lindemann K; van Beekhuizen HJ; Trum H; Boll D; Werner HMJ; van Lonkhuijzen LRCW; Yigit R; Forsse D; Witteveen PO; Galaal K; van Ginkel A; Bignotti E; Weinberger V; Sweegers S; Kroep JR; Cabrera S; Snijders MPLM; Inda MA; Eriksson AGZ; ; Krakstad C; Romano A; van de Stolpe A; Pijnenborg JMA
Am J Obstet Gynecol; 2021 Oct; 225(4):407.e1-407.e16. PubMed ID: 34019887
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of KRAS Gene Expression and LCS6 Variant in Genomic and Cell-Free DNA of Iranian Women With Endometriosis.
Farahani MS; Shahbazi S; Moghaddam SA; Mahdian R
Reprod Sci; 2015 Jun; 22(6):679-84. PubMed ID: 25361550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]